MAPT and Alzheimer disease: Additionally, a cohort study has shown that elevated plasma p-tau 181 levels are closely correlated with the occurrence of psychiatric symptoms (delusions and hallucinations) in AD, emphasizing the potential use of plasma p-tau 181 as a biomarker for neuropsychiatric diseases in AD [53].